Relmada Therapeutics(RLMD)
$4.43+0.16 (+3.75%)
RLMD
Relmada Therapeutics financials statements
$4.43
At close:+0.16 (+3.75%)
Want to see RLMD full AI Analyst Report?
Relmada Therapeutics (RLMD) Ratios
446 Followers
Relmada Therapeutics Ratios
RLMD's free cash flow for Q2 2026 was $-9.61M. For the 2026 fiscal year, RLMD's free cash flow was increased by $0.00 and operating cash flow was $-9.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 |
| Quick Ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 |
| Cash Ratio | 0.54 | 0.37 | 0.34 | 0.43 | 2.95 |
| Solvency Ratio | -7.66 | -7.77 | 0.40 | -12.59 | -8.35 |
| Operating Cash Flow Ratio | -7.12 | -5.03 | -4.24 | -8.32 | -6.10 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 86.49M | $ 35.50M | $ 85.31M | $ 140.40M | $ 208.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.29 | 1.14 | 1.09 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.06 | 0.05 | -0.83 | 0.03 | 0.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.10% | 95.34% | 95.27% | 97.39% | 100.04% |
| Return on Assets (ROA) | -61.05% | -174.56% | -101.27% | -102.71% | -56.31% |
| Return on Equity (ROE) | -66.33% | -225.15% | -115.74% | -111.83% | -60.38% |
| Return on Capital Employed (ROCE) | -67.49% | -236.14% | -121.49% | -114.82% | -60.36% |
| Return on Invested Capital (ROIC) | -67.49% | -236.14% | -121.49% | -114.82% | -60.36% |
| Return on Tangible Assets | -61.05% | -174.56% | -101.27% | -102.71% | -56.31% |
| Earnings Yield | -30.09% | -509.90% | -318.66% | -607.49% | -158.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 |
| Free Cash Flow Per Share | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -12914801.50 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -12914801.50 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -24.01% | -329.96% | -166.63% | -401.53% | -116.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.33 | -0.20 | -0.31 | -0.16 | -0.63 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.20 | 0.44 | 0.36 | 0.18 | 0.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.16 | -0.30 | -0.60 | -0.25 | -0.86 |
| Price-to-Operating Cash Flow Ratio | -4.16 | -0.30 | -0.60 | -0.25 | -0.86 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.01 | 0.01 | 0.01 | -0.01 |
| Enterprise Value Multiple | -3.26 | -0.15 | 5.48 | -0.13 | -0.28 |
| Enterprise Value | 187.19M | 11.83M | 26.91M | 20.46M | 34.72M |
| EV to EBITDA | -3.26 | -0.15 | 5.48 | -0.13 | -0.28 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.09 | -0.23 | -0.52 | -0.20 | -0.38 |
| EV to Operating Cash Flow | -4.09 | -0.23 | -0.52 | -0.20 | -0.38 |
| Tangible Book Value Per Share | 2.19 | 1.18 | 2.84 | 4.74 | 11.87 |
| Shareholders’ Equity Per Share | 2.19 | 1.18 | 2.84 | 4.74 | 11.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.97 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.65 | 0.52 | 0.66 | 0.73 |
Currency in USD
